Karyopharms Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
Summary
Karyopharm announced that its Phase 3 SENTRY trial data will receive a late-breaking oral presentation at the 2026 EHA Congress. The company highlighted results for selinexor plus ruxolitinib in myelofibrosis, including sustained spleen volume reduction, symptom improvement, and a promising overall survival signal. It also shared a post-hoc analysis suggesting that SVR35 may predict overall survival. The release reinforces Karyopharm's continued clinical development work for selinexor across hematology and oncology indications.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected